# McKESSON CORPORATION (MCK) FY2027 Q1 P&L / Income Statement

- Company: McKESSON CORPORATION (MCK)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q1 FY2027 10-Q, filed 2026-08-05, accession number 0000927653-26-000234
- Page: https://plicit.ai/financials/mck/fy2027-q1-income-statement
- Chart image: https://plicit.ai/charts/mck-fy2027-q1-income-statement-sankey.png

## Chart details: Revenue by Business Segment

Income statement for 2026-04-01 through 2026-06-30. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 105,380,000,000 US dollars
- **Cost of sales**: 101,695,000,000 US dollars
- **Gross profit**: 3,685,000,000 US dollars
- **Total operating expenses**: 2,366,000,000 US dollars
- **Operating income**: 1,319,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 11,000,000 US dollars
- **Income before income taxes**: 1,308,000,000 US dollars
- **Income tax expense**: 276,000,000 US dollars
- **Net income**: 1,032,000,000 US dollars
- **North American Pharmaceutical**: 86,773,000,000 US dollars
- **Oncology & Multispecialty**: 14,222,000,000 US dollars
- **Prescription Technology Solutions**: 1,566,000,000 US dollars
- **Medical-Surgical Solutions**: 2,819,000,000 US dollars
- **Selling, distribution, general, and administrative expenses**: 2,264,000,000 US dollars
- **Claims and litigation charges, net**: negative 34,000,000 US dollars
- **Restructuring, impairment, and related charges, net**: 136,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to McKESSON CORPORATION: $614.00 M; to noncontrolling interests: $418.00 M.